The Relative Strength (RS) Rating for Bio-Techne moved up into a higher percentile Friday, as it got a lift from 69 to 74.
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
History shows that the market's biggest winners tend to have an RS Rating of at least 80 as they begin their largest climbs. See if Bio-Techne can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Bio-Techne is working on a consolidation with an 85.57 buy point. See if it can clear the breakout price in volume at least 40% above average.
Earnings grew 2% last quarter, up from -11% in the prior report. Revenue also increased, from 2% to 5%. The next quarterly numbers are expected on or around Feb. 4.
Bio-Techne holds the No. 4 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte is the top-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
